Trends in serious infections in rheumatoid arthritis

Journal of Rheumatology

Volumn 40, Issue 5, 2013, Pages 611-616

  Ni Mhuircheartaigh, Orla M ^a   Matteson, Eric L ^a   Green, Abigail B ^a   Crowson, Cynthia S ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Biologic agents; Infection; Rheumatoid arthritis

Indexed keywords

1 AMINO 1,3 CYCLOPENTANEDICARBOXYLIC ACID; 2 (2' CARBOXYCYCLOPROPYL)GLYCINE; 2 AMINO 3 PHOSPHONOPROPIONIC ACID; 3,5 DIHYDROXYPHENYLGLYCINE; 4 CARBOXY 3 HYDROXYPHENYLGLYCINE; ALPHA METHYL 4 CARBOXYPHENYLGLYCINE; ALPHA METHYL 4 TETRAZOLYLPHENYLGLYCINE; DIZOCILPINE; GLUTAMIC ACID; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; TRANS AZETIDINE 2,4 DICARBOXYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL PROTECTION; CELL SURVIVAL; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT;

BIOLOGIC AGENTS; INFECTION; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; INCIDENCE; INFECTION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINNESOTA; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84876901188     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121075     Document Type: Article

References (28)

1. Doran M, Crowson C, Pond G, O'Fallon W, Gabriel S. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002;46:2287-93.
2. Doran M, Crowson C, Pond G, O'Fallon W, Gabriel S. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
3. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6. (Pubitemid 32525142)
4. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21. (Pubitemid 34137339)
5. Wallis RS. Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin North Am 2011;25:895-910.
6. Hernandez-Cruz B, Garcia-Arias M, Ariza Ariza R, Martin Mola E. [Rituximab in rheumatoid arthritis: A systematic review of efficacy and safety]. Reumatol Clin 2011;7:314-22.
7. Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2847-55.
8. Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res 2012;64:1480-9.
9. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
11. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010;62:1576-82.
12. Melton LJ 3rd. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
13. Turesson C, Jacobsson L, Bergstrom U. Extra-articular rheumatoid arthritis: Prevalence and mortality. Rheumatology 1999;38:668-74. (Pubitemid 29507338)
14. Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: A population-based study. J Rheumatol 2011;38:983-9.
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706. (Pubitemid 29126745)
16. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statistics 1988;16:1141-54.
17. Gill R. Understanding Cox's regression model. Experientia Suppl 1982;41:187-99.
18. Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:729-52.
19. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971;14:135-7.
20. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 1998;95:14447-52. (Pubitemid 28549387)
21. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97:9203-8. (Pubitemid 30626698)
22. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
23. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
24. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46.
25. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St. Sauver JL, et al. The epidemiology of community-acquired Clostridium difficile infection: A population-based study. Am J Gastroenterol 2012;107:89-95.
26. Laret V, Sion C, Bataille C, Hustinx R, Reginster M. [Clinical case of the month: clostridium difficile colitis]. Rev Med Liege 2006;61:750-2.
27. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253-64.
28. HCUP Reports. Healthcare Cost and Utilization Project (HCUP). December 2012. Rockville, MD: Agency for Healthcare Research and Quality. [Internet. Accessed February 6, 2013.] Available from: www.hcup-us.ahrq.gov/reports.jsp